Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25257331 | 0.77 | NAAA (0.44) | IDO1CHRM3NAAASIGMAR1FAAH | |
| SCHEMBL704571 | 0.74 | ABCB1 (0.41) | CHRM3 | |
| SCHEMBL27223224 | 0.74 | ABCB1 (0.41) | CHRM3 | |
| SCHEMBL23043429 | 0.74 | ABCB1 (0.41) | CHRM3 | |
| SCHEMBL3305393 | 0.73 | CHRM3 (0.35) | CHRM3NAAAFAAHMGLL | |
| SCHEMBL2426349 | 0.72 | NAAA (0.38) | CHRM3NAAAMAOBMAOA | |
| SCHEMBL17099295 | 0.71 | AGTR2 (0.47) | IDO1NAAASIGMAR1 | |
| SCHEMBL27223928 | 0.71 | CTSL (0.41) | NAAASIGMAR1 | |
| SCHEMBL31441834 | 0.70 | SLC6A3 (0.36) | IDO1SIGMAR1FAAH | |
| SCHEMBL31441914 | 0.70 | SLC6A3 (0.36) | IDO1SIGMAR1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | IDO1 968/4885CHRM3 4846/4885NAAA 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.